Cancer-induced cachexia involves weight loss, catabolic activity, and inflammation. We have evaluated the effects of various treatments (GH, insulin (INS), indomethacin (IND), and all possible combinations) on cancer cachexia in a mouse model. BALB/c mice that were implanted with colon-26 adenocarcinoma developed cachexia in 9 days. Body weight, tumor volume, tumor-free weight, inflammatory cytokines (tumor necrosis factor-a (TNF-a), interleukin 6 (IL6)), and nutritional markers (glucose (Glu), albumin, triglycerides (TGs)) of treatment and control groups were monitored. In the cachexia group, there was a significant decrease in tumor-free bodyweight by day 11. Treatment with GHCINSCIND significantly alleviated tumor-free bodyweight reduction and cachexiainduced changes in nutritional markers and cytokines, and prolonged survival time. GHCINSCIND treatment was more effective than other treatment combinations in elevating Glu and TGs, reducing TNF-a and IL6 levels, and prolonging survival time. In conclusion, GHCINS CIND alleviated cachexia symptoms in a murine model of cancer cachexia.
Introduction
Cachexia accounts for about 25% of cancer-related mortalities (Lelbach et al. 2007) . The main manifestations of cancer-induced cachexia are weight loss, malnutrition, lean muscle wasting, anorexia, and metabolic disorders, and these lead to progressive glyconeogenesis, high muscle albuminolysis, and increased lipolysis (Saini et al. 2006) . Cancer-associated weight loss of more than 6% is associated with decreased survival time for patients with metastatic breast cancer, colon cancer, non-small cell lung cancer, and prostate cancer, but not pancreatic cancer ( Jatoi 2008) .
The pathogenesis of cancer-associated cachexia is multifactorial, and the causes have been extensively studied. Lean muscle wasting is due to reduced protein synthesis and increased protein degradation (Tisdale 2009 ). The systemic inflammatory response associated with cancer cachexia is characterized by elevated levels of tumor necrosis factor-a (TNF-a), interleukin 6 (IL6), TWEAK (a member of the TNF family), IL1 receptor antagonist, and C-reactive protein (McMillan 2009) . At the physiological level, elevation of these cytokines leads to increased energy expenditure, suppression of appetite, catabolic activity, and muscle wasting (Argilés et al. 2009 ). Elevation of TNF-a and IL6 also promotes lipolysis, although adipose tissue is not the major source (Agustsson et al. 2007) .
There are currently no standard practice guidelines for treatment of cancer cachexia (Mantovani & Madeddu 2010) , but five therapeutic strategies are under investigation: i) steroids, ii) nonsteroid anti-inflammatory drugs and biological modifiers specific for TNF-a, iii) progesterone derivatives, iv) omega-3 fatty acids with anti-inflammatory activity and essential nutritional value (Lelbach et al. 2007) , and v) anabolic agents that enhance protein synthesis, including GH (Berman et al. 1999) and insulin (INS; Lundholm et al. 2007) . The use of progesterone derivatives has been criticized because these agents induce tumor weight gain in animal models (Argilés et al. 2004 ) and the weight gain in megesterol-treated cancer patients is mainly due to water retention and increased fat tissue (Lelbach et al. 2007) .
A previous clinical study showed that daily administration of s.c. INS to cachectic cancer patients improved micronutrient absorption and fat metabolism (Lundholm et al. 2007) . INS has anabolic activity and can antagonize IL6 signaling in adipose tissue (Andersson et al. 2007 ). Conversely, INS-dependent activation of RAC-b serine/threonineprotein kinase-2 (AKT2), which is important in the mediation of its downstream metabolic actions, is markedly inhibited by IL6 (Senn et al. 2002) . TNF-a impedes some functions of INS, such as receptor engagement (O'Connor et al. 2008) .
A clinical study of patients with cancer cachexia indicated that indomethacin (IND) suppressed cyclooxygenase (COX), TNF-a, and IL6, improved energy homeostasis, reduced the amount of weight loss, and reduced chronic inflammation (Lundholm et al. 2004 ). An animal study showed that IND decreased the activation of ubiquitin-dependent proteases involved in protein degradation, reduced nuclear factor kB (NF-kB) activation, reduced the levels of TNF-a and IL6, and alleviated muscle wasting (Zhou et al. 2003) .
GH has well-known anabolic affects, including promotion of nutrient assimilation, protein synthesis, and fatty acid oxidation (Carli et al. 1997) . Importantly, a study of tumorbearing mice indicated that stimulation of the GH-insulinlike growth factor (IGF) axis did not promote tumor growth (Khan et al. 2005) . A clinical study of cancer patients indicated that administration of GH alone or in combination with INS led to bodyweight gain and increased upper arm muscle mass and strength (Berman et al. 1999) .
Thus, INS, IND, and GH can each alleviate some manifestations of cachexia, but the efficacy of these treatments needs to be improved. Moreover, because of its multifactorial pathogenesis, cachexia may be more responsive to combination therapy (Mantovani & Madeddu 2010) . The presence of multiple interactions in the INS and proinflammatory cytokine pathways suggests that there may be benefits for using multiple agents for treatment of cachexia.
In this study, we examined the effect of GH (to stimulate anabolic activity), INS (to stimulate anabolic and anti-inflammatory activity), and IND (to block inflammation) alone and in all possible combinations in a murine model of cancer cachexia. A colon-26 (C-26) adenocarcinoma specimen was purchased from the Institute Materia Medica, Chinese Academy of Medical Sciences (Beijing, People's Republic of China). Tumors were implanted under the left armpit of mice following the third or fourth passage.
Materials and Methods

Reagents
Cancer cachexia models
All mice were initially acclimated for 7 days. A total of 128 mice were implanted with tumor cells. A homogenate of 50 mg (2-3 mm 3 ) minced solid murine C-26 adenocarcinoma in S-Z CHEN and Z-G QIU . Triple therapy alleviates cancer cachexia 0 . 1 ml of sterile 0 . 9% NaCl was injected s.c. into the armpits (day 0). A group of 10 mice with no tumor cell implantation was used as 'healthy control'; a group of 10 mice with tumor cell implantation but no treatment was used as 'cachexia control'. The physical activity, fur condition, bodyweight, general health, and tumor inoculation site were monitored every 2 days. Food intake was measured at 1000 h daily. The tumor was considered to have ellipsoid or prolate spheroid geometry. We measured tumor volume (V, cm 3 ) as described by Zhou et al. (2003) . In particular, V was estimated as (a!b 2 )/2, where a is length and b is width. Tumor mass (M ) was estimated by the formula (MZV!r), where r is the tumor density at the time of killing or expiration. When the tumor-free weights of tumor-bearing mice and healthy mice (Agustsson et al. 2007) were significantly different, and cachexia symptoms (poor physical activity, asthenia, piloerection, shedding, and nonglossy fur) became obvious, cachectic mice were randomly divided into an untreated group (NZ16; i.p. injection with PBS) and seven treatment groups (NZ16). The treatment groups were GH, INS, IND, GHCINS, GHCIND, INSCIND, and GHCINSCIND. I.p. administration of GH (0 . 5 mg/kg per day), INS (0 . 5 mg/kg per day), and/or IND (0 . 5 mg/kg per day) began on day 9 (at the onset of cachexia) and continued daily, according to mouse weight and the dosage table.
Ten mice from each group were killed on day 16, with blood samples collected from orbital veins prior to killing. There was significant mortality of the experimental animals at 16 days, so we terminated the experiment at this point. An average of 0 . 6 ml blood was withdrawn from each mouse, and 20-40 ml were used for each measurement. Duplicate samples were not possible because of the limited amount of serum recovery from each mouse. Tumors were removed and tumors and tumor-free weights were determined. Survival times for the remaining mice in each group (six mice for each group) were recorded and analyzed.
Biochemical and serological markers
On day 16, blood samples were collected from orbital veins and stored at K708C. Levels of TNF-a and IL6 were determined by ELISA kits purchased from R&D Systems, Inc. Serum glucose (Glu), triglyceride (TG), and albumin were measured by an automated analyzer (BA-88 MINDRAY Biochemistry Analyzer, Shenchen, People's Republic of China). 
Statistical analysis
Means and S.D.s were calculated for each group. Comparisons were performed using a mixed model considering repeated measure effect with post hoc comparison adjusted by the Bonferroni method. The model was two-way factorial with variance components covariance structure and the degree of freedom method was between-within (subject) method. The log-rank test was used for survival analysis. Data were analyzed using SAS 9.0 (SAS Institute, Inc., Cary, NC, USA). A P value !0 . 05 was considered statistically significant.
Results
Tumor growth and cachexia
The mice showed symptoms of cachexia on day 9 (cachexia onset) after the tumor transplantation. These mice exhibited delayed responsiveness, poor physical activity, scruffy fur, piloerection, and darkening of dorsal hairs. A two-way repeated measure ANOVA indicated that all the groups had significant weight change (data not shown) and increase in tumor volume over time (Fig. 1) . For the cachexia control group, the tumor volume increased from 1 . 49G0 . 25 cm 3 on day 9 to 4 . 73G0 . 71 cm 3 on day 16. On days 13 and 16, there were significant differences in total bodyweight across all treatment groups (data not shown) but the tumor volume was not significantly affected by any of the treatments (Fig. 1) .
Tumor-free bodyweight
In the cachexia control group, there was a significant reduction in tumor-free bodyweight (total body weight minus tumor mass) beginning on day 11 (Fig. 2) . Relative to the cachexia control group, mice given GHCINSCIND had greater tumor-free bodyweights on days 13 and 16 (see Fig. 2 ). Pair-wise comparisons indicated additional statistically significant differences in tumor-free bodyweight between several of the treatment groups on days 11, 13, and 16 (see Fig. 2 ). However, none of the treatments restored tumor-free bodyweight to that of the healthy controls.
Nutritional markers and cachexia-related cytokines
The cachexia control group experienced a significant reduction in tumor-free bodyweight on day 11 (Fig. 2) . Relative to healthy controls, this group also experienced significant reductions in three nutritional markers (Fig. 3A-C ) and significant elevations in two cachexia-related cytokines ( Fig. 3D and E) . Treatment with GHCINSCIND significantly alleviated the cachexia-induced changes in Glu, TG, TNF-a, and IL6 (Fig. 3) . However, the cachexia markers in the GHCINSCIND group did not return to those of healthy controls (Fig. 3) . Tumor-bearing mice treated with GHCINSCIND had significantly higher levels of Glu (Fig. 3A) and lower levels of IL6 (Fig. 3E ) than those given other treatments. Tumor-bearing mice treated with GHC INSCIND also had significantly higher levels of TG (Fig. 3C ) and lower levels of TNF-a (Fig. 3D ) than mice treated with GH, INS, or GHCINS.
Survival time
Finally, we examined the effect of our seven treatments on survival time of mice that were not killed (six mice per group; Fig. 4 ). Log-rank tests indicated that the survival curves were significantly different among various treatments (P!0 . 0001) and that the GHCINSCIND treatment group had a significantly longer survival time than the cachexia control group and the other treatment groups (P!0 . 05 for all comparisons). All mice in the healthy control group survived for 16 days.
Discussion
Cancer cachexia is a common condition that complicates cancer treatment strategies and reduces survival time ( Jatoi 2008) . This study demonstrated that a multimodal treatment strategy that targets three different pathogenic mechanisms of cachexia ameliorates cancer cachexia in a mouse model. Although anorexia is a common feature of cancer-induced cachexia in humans (Lelbach et al. 2007) , we found no effect of cachexia on food intake in our mouse model, consistent with a previous report (Zhou et al. 2003) .
On days 13 and 16, there were significant differences among the treatment groups. Although there was no statistical difference between the healthy control and cachexia control groups in total body weight (data not shown), the tumor-free body weight of the cachexia control group was significantly Figure 4 The Kaplan-Meier survival curve of mice in each of the seven treatment groups and the untreated (cachexia) group, nZ6. The survival curves were significantly different among various treatments (log-rank test, P!0 . 0001). The GHCINSCIND treatment group had a significantly longer survival time than the cachexia group and the other treatment groups (P!0 . 05 for all comparisons).
S-Z CHEN and Z-G QIU . Triple therapy alleviates cancer cachexia lower than that of the healthy control group (Fig. 2) . This is simply because the cachexia control group had a large tumor mass (Fig. 1) . In addition, total body weight and tumor-free body weight (Fig. 2 ) of mice treated with GHCINSCIND were significantly higher than those of the cachexia control group. This suggests that GHCINSCIND treatment partially reverses the weight loss induced by cachexia.
INS can induce anabolic and anti-inflammatory activities in humans with cancer (Dandona et al. 2001) . Consistent with this clinical finding, our results indicate that INS alone or in combination with other treatments (i.e. IND) increased tumor-free bodyweight of cachectic mice and led to significantly longer survival times. Some research has shown that INS antagonizes IL6 signaling in adipose tissue via the methyl ethyl ketone/mitogen-activated protein kinase pathways (Andersson et al. 2007) , but other research suggests that INS stimulates IL6 production (LaPensee et al. 2008) . In our cachectic mouse model, we found that administration of INS alone, INSCIND, or INSCINDCGH significantly reduced serum levels of IL6. IL6 is a potential prognostic marker for survival time of patients with cancer cachexia (Ebrahimi et al. 2004) . Thus, our observations suggest that INS may be partially responsible for the alleviation of cachexia symptoms and prolongation of survival time.
In our mice, GH did not promote growth of the implanted C-26 adenocarcinomas. Similarly, GH has been reported to have no effect on the growth of human bronchoaveolar carcinoma and human breast adenocarcinoma (Khan et al. 2005) . GH increases anabolic activity, and some of its effects may also be mediated by increasing the immune response (Redelman et al. 2008) . However, we observed no effect of GH on the slowing of tumor growth during the course of our relatively short (25-40 days) study. GH did not significantly reduce inflammatory cytokines nor elevate nutritional markers relative to untreated cachectic control mice, and GH treatment alone did significantly increase survival time. One possibility is that the modest (but statistically insignificant) GH-induced modulation of nutritional markers was insufficient to increase survival time.
IND inhibits COX and suppresses the production of proinflammatory cytokines. A previous clinical study reported that malnourished cancer patients treated with IND experienced improved nutritional status, longer survival time, and better quality-of-life (Lundholm et al. 2004 ). Our IND groups had significantly higher tumor-free bodyweight, Glu, and TG, longer survival times, and reduced levels of proinflammatory cytokines. This suggests that proinflammatory cytokines may affect the nutritional status of patients with cancer cachexia (Argilés et al. 2009 , Tisdale 2009 ).
Mice treated with GHCINSCIND had significantly better survival times than the cachexia control group and all other treatment groups. Moreover, mice given this triple treatment had improved nutritional and inflammatory markers. Crosstalk and feedback loops between the INS and proinflammatory cytokine pathways may be responsible for these effects. In agreement with a recent review article (Mantovani & Madeddu 2010) , our results suggest that combination therapy (GHCINSCIND) may be an effective strategy for the alleviation of cancer cachexia.
GH, INS, and IND all have extensive clinical histories and are inexpensive. We suggest that future studies examine the pharmacokinetics of these three agents when given together, before they are studied in clinical trials. All animal models are limited in that they do not fully mimic responses in a heterogeneous human population with different types of cancer. Moreover, our mice were not INS resistant, whereas cancer cachexia patients usually are INS resistant (Lelbach et al. 2007 ). In addition, our doses of INS, GH, and IND were based on previous reports and were not optimized by titration; this may be why none of our treatments reduced cachexia-associated abnormalities relative to those of the healthy control group. Finally, an adverse effect of the IND and INS treatment was not an objective in this study, but it is possible that a side effect, such as hypertrophy of some body parts, may be a confounding factor.
In summary, our study demonstrated that treatment of a murine cancer cachexia model with GHCINSCIND alleviated cachexia-associated symptoms, increased tumor-free bodyweight, increased Glu and TG, reduced TNF-a and IL6, and increased survival time. However, none of our treatment regimens were able to fully reverse all the symptoms associated with cancer cachexia. These three agents have long clinical histories and are inexpensive, so it is feasible to evaluate similar combination therapies in clinical trials of cancer cachexia.
